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356Objective: The role of surgery in patients with N2 non–small cell lung cancer is debated. The aim of this study
was to evaluate the results of surgical resection after induction chemotherapy.
Methods: We retrospectively reviewed the cases of patients with N2 non–small cell lung cancer who underwent
neoadjuvant chemotherapy followed by resection between 2001 and 2007. They all had tumors deemed resectable.
Results: One hundred seventy-five patients entered the study. Most of them received 2 or 3 cycles of chemother-
apy (81%), in all cases platinum-based regimens. Chemotherapy response rate was 62%. Operations included 96
lobectomies/bilobectomies and 79 pneumonectomies. Complete resection rate was 94%, and perioperative mor-
tality was 4.5%. A pathologic mediastinal downstaging was found in 39% of patients. Overall median survival
time and 5-year survival were 34.7 months and 30%, respectively. Survival was affected by clinical response
(median survival time 51 months and 5-year survival 42% for responders versus 19 months and 10% for non-
responders) and by nodal downstaging (51 months and 45% versus 25% and 22%). In the group of responders,
nondownstaged patients showed satisfying survival (median survival time 30 months, 5-year survival 30%). In
the group of nonresponders, survival was unsatisfactory when a lobectomy was performed (median survival time
20 months, 5-year survival 13%) and poor in case of pneumonectomy (15 months and 6%). Multivariate analysis
found 4 factors significantly affecting survival: clinical response, nodal downstaging, number of chemotherapy
cycles, and histopathologic response.
Conclusions: Surgery after chemotherapy could be effective for selected patients with N2 non–small cell lung
cancer. Survival for responders is satisfactory, even in case of persistent N2 disease. Prognosis for nonresponders
is disappointing. (J Thorac Cardiovasc Surg 2010;140:356-63)Earn CME credits at
http://cme.ctsnetjournals.org
Retrospective series, some phase II trials, and a few phase III
trials suggested improved long-term survival for patients with
N2 non–small cell lung cancer (NSCLC) treated with neoad-
juvant therapy followed by surgical resection compared with
surgery alone.1-8 Nevertheless, the best treatment option for
this group of patients is still debated and the role of surgery
after induction therapy is not yet clearly defined. In fact,
this subgroup is heterogeneous, including patients with
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The Journal of Thoracic and Cardiovascular Surgthose with bulky mediastinal lymph node involvement,
which may not be amenable to a radical resection. The
variability in chemotherapy regimens, the addition of
radiation therapy to induction protocols, different methods
of staging and restaging, and different indications for
surgery after chemotherapy response represent further
variables, as well as significant differences in postoperative
mortality, especially in the case of pneumonectomy.9-12
Because of this heterogeneity, the data in the literature are
difficult to evaluate. Recently, the European Organisation
for Research and Treatment of Cancer (EORTC) trial,
comparing surgery versus radiotherapy after neoadjuvant
chemotherapy in unresectable N2 NSCLC, showed no im-
provement in survival for the surgical group.13 By contrast,
the Intergroup 0139 trial, including N2 patients deemed ini-
tially to have resectable disease, showed that chemoradiation
followed by surgery compared with chemoradiation alone
provided better progression-free survival (PFS).12
Heterogeneity of results led to different therapeutic ap-
proaches. Guidelines published by the American College
of Chest Physicians have recently stated that in patients
with NSCLC with N2 disease identified preoperatively,
neoadjuvant therapy followed by surgery is not recommen-
ded except as part of a clinical trial, even if the disease isery c August 2010
Abbreviations and Acronyms
CT ¼ computed tomography
EORTC ¼ European Organisation for Research and
Treatment of Cancer
MST ¼ median survival time
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
PFS ¼ progression-free survival
Stefani et al General Thoracic Surgery
G
T
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ceived chemoradiation induction therapy as a part of a clini-
cal trial, pneumonectomy is not recommended. Conversely,
in France, a consensus statement has approved two therapeu-
tic options for patients with resectable N2 NSCLC, both in-
cluding surgery, with chemotherapy in a neoadjuvant or
adjuvant setting.15
To identify which subjects could benefit from surgery
after induction therapy, we reviewed our experience with
patients treated with neoadjuvant chemotherapy for N2
NSCLC followed by surgical resection.
PATIENTS AND METHODS
A retrospective analysis was performed of all patients who underwent
surgical resection after neoadjuvant chemotherapy for N2 NSCLC at our
institution from January 2001 to December 2007. Eligibility criteria were
histologically proved NSCLC with lymph node involvement in the ipsilat-
eral mediastinum, platinum-based induction chemotherapy, anatomic major
pulmonary resection, and radical lymphadenectomy with curative intent.
Patients with a T4 lesion deemed resectable by the surgeon before chemo-
therapy were included. Bronchioloalveolar carcinomas, Pancoast tumors,
patients with N3 involvement, malignant pleural effusions, or resectable sol-
itary metastases were excluded (nodules in the other lobe of the ipsilateral
lung, detected intraoperatively and resected, were included). All the patients
who entered the study had potentially resectable tumors and they underwent
combined treatment to improve oncologic outcome.
Pretreatment evaluation consisted of computed tomography (CT) scan of
the chest, upper abdomen, and brain and fiberoptic bronchoscopy for all pa-
tients. Mediastinoscopy was not routinely performed and positron emission
tomography (PET) has been systematically performed only since 2004. Tu-
mors were staged according to the 2002 version of TNM staging. Selection
of patients for the study was also based on the method of assessment of N2
positivity: all patients with positive mediastinoscopy or positive PET and
CT scan were included. Some patients, whose disease was staged N2 by
CT only were also included: patients with N2 involvement on specimen ex-
amination and patients with bulky N2 at CT scan (short-axis diameter>2
cm) and/or multiple stations involvement.
Because our surgical department is a tertiary referral center and patients
are addressed by physicians from different hospitals, no uniform protocol
was used for induction or adjuvant treatment.
After completion of chemotherapy, response was assessed according to
the World Health Organization criteria by CT scan and fiberoptic bronchos-
copy16: complete response, disappearance of all disease on radiographic and
bronchoscopic (when done) examination; partial response, greater than
50% reduction of the volume of all measurable lesions; stable disease, no
detectable change in tumor volume of all lesions or change in the size of
all measured lesions between a 50% reduction and a 25% increase, with
no additional disease discovered; progressive disease, increase of more
than 25% of all measured lesions or appearance of new lesions. ObjectiveThe Journal of Thoracic and Caresponse consisted of complete response or partial response. Because our
policy is to contraindicate surgery in case of progressive disease, only pa-
tients with objective response or stable disease were operated on.
A resection was considered complete (R0) when there was no residual or
microscopic tumor at the bronchial or vascular margins and no residual dis-
ease in the mediastinal area. Nodal downstaging was considered when ab-
sence of gross and microscopic disease in the resected mediastinal nodes
was found (pN0). Routine histochemistry was generally used for the analy-
sis. Major histopathologic response was defined as fewer than 10% residual
tumor cells in the primary lesion.13 No evidence of disease in the lung and
lymph nodes was considered to be a complete histopathologic response.
Perioperative mortality included 30-day mortality and in-hospital deaths.
All data were recorded by the revision of clinical charts, imaging, opera-
tive, and pathologic reports. Complete follow-up information was achieved
for each patient with respect to survival, recurrence and adjuvant treatment.
Statistical analysis was conducted using the SPSS statistical software
(SPSS Inc, Chicago, Ill). Frequencies were compared with the c2 test or
Fisher’s exact test for categorical variables. The t test and analysis of
variance were performed when comparing continuous variables. Overall
survival was calculated from the first day of chemotherapy until death
from any cause or the date of last follow-up. PFS was calculated from the
date of chemotherapy start to the date of recurrence or death from any cause.
Survival analysis was performed according to the Kaplan–Meier method
and curves were compared with the log–rank test. A multivariate analysis
of independent prognostic factors was calculated with the Cox proportional
hazards regression model; in case of highly correlated variables, separated
models were performed. A P< .05 was considered as significant.RESULTS
One hundred seventy-five patients fulfilled the selection
criteria of the retrospective analysis and represent the popu-
lation of the study. The main patients’ clinical features are
listed in Table 1. The most common comorbidities were
chronic obstructive pulmonary disease in 105 (60%)
patients and cardiovascular diseases in 69 (39%). Seventy-
eight (45%) patients underwent invasive staging of the me-
diastinum by mediastinoscopy or anterior mediastinotomy,
41 (23%) had both positive CT and PET scan results, and
56 (32%) were staged by CT scan only. In this latter group,
34 (61%) patients remained in pathologic N2 class whereas
22 were found to have absence of disease in mediastinal
nodes at postoperative analysis: in this subgroup there
were 11 patients with clinically bulky N2 and 11 with
multiple-station clinical involvement. Tumor was consid-
ered fully resectable in 163 (93%) patients and only margin-
ally resectable in 12.
All chemotherapy regimens contained platinum, in asso-
ciation with gemcitabine in 79 (45%) cases, vinorelbine in
58 (33%), paclitaxel in 29 (17%), and other drugs in 9
(5%). Seventy-four (42%) patients had 3 cycles of chemo-
therapy, 68 (39%) had 2 cycles, 31 (18%) had 4 cycles or
more, and 2 had only 1 cycle. One hundred nine (62%) pa-
tients had an objective response to chemotherapy (9 radio-
graphic complete responses and 100 partial), and 66 had
stable disease.
Surgical and pathologic features are reported in Table 2.
Twenty-six (15%) patients underwent bronchial sleeve re-
section: 18 sleeve lobectomies (22% of lobectomies) andrdiovascular Surgery c Volume 140, Number 2 357
TABLE 1. Main clinical characteristics of the 175 patients
Variable No. of patients (%)
Sex
Male 137 (78%)
Female 38 (22%)
Age (y) 58.2 (39–78)
Smoking history
Yes 147 (84%)
No 28 (16%)
Symptoms
Yes 121 (69%)
No 54 (31%)
Predicted postoperative FEV1 (%) 59.8 (32–109)
Performance status (ECOG)
0 34 (19%)
1 96 (55%)
2 40 (23%)
3 5 (3%)
Comorbidity
Yes 143 (82%)
No 32 (18%)
Tumor size (mm) 53.2 (15–150)
N2 levels
Single 119 (68%)
Multiple 56 (32%)
N2 compartment
Superiors 70 (40%)
Inferiors 27 (15%)
APW 22 (13%)
Two or more 56 (32%)
Bulky N2
Yes 44 (25%)
No 131 (75%)
Stage
IIIA 155 (89%)
IIIB 20 (11%)
FEV1, Forced expiratory volume in 1 second; ECOG, Eastern Cooperative Oncology
Group; APW, aortopulmonary window. Age, predicted postoperative FEV1, and tumor
size are expressed in terms of mean and range minimum–maximum. Predicted postop-
erative FEV1 was calculated on 164 patients (radionuclide scans data not available for
11 patients). All patients with stage IIIB disease were classified as T4.
TABLE 2. Main operative and pathologic features
Variable No. of patients (%)
Type of resection
Lobectomy 82 (47%)
Bilobectomy 14 (8%)
Pneumonectomy 79 (45%)
Histology
Adenocarcinoma 82 (47%)
Squamous carcinoma 65 (37%)
Others 28 (16%)
Pathologic N
N0 49 (28%)
N1 19 (11%)
N2 107 (61%)
Pathologic stage
Stage 0 10 (6%)
Stage I 26 (15%)
Stage II 19 (11%)
Stage IIIA 93 (53%)
Stage IIIB 22 (12%)
Stage IV 5 (3%)
Radicality
R0 164 (94%)
R1 9 (5%)
R2 2 (1%)
N2 levels*
Single 73 (68%)
Multiple 34 (32%)
N2 compartments*
Superiors 34 (32%)
Inferiors 19 (18%)
Aortopulmonary window 20 (19%)
Two or more 34 (32%)
*Rates are calculated on 107 patients with pN2 disease.
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mies). All IIIB tumors were T4 N0-2; T4 lesions were repre-
sented by satellite nodule(s) in 11 cases and by involvement
of mediastinal structures in 13. All the M1 tumors were due
to the presence of a nodule in the other lobe of the ipsilateral
lung; in all cases the nodule was resected. Mediastinal down-
staging occurred in 68 (39%) patients, in 19 cases to N1 dis-
ease and in 49 to N0. A major histopathologic response was
observed in 35 (20%) patients, with complete pathologic
remission in 10 (6%); in these latter cases, CT scan had
showed 3 complete responses and 7 partial. Thirty-two of
35 patients with major histopathologic response also had
mediastinal downstaging.
Eight deaths occurred in the postoperative period (4.5%),
6 after pneumonectomy (7.6% of all pneumonectomies), of358 The Journal of Thoracic and Cardiovascular Surgwhich 4 were on the right side, and 2 after lobectomy
(2.1% of all lobectomies). One hundred twenty-nine
(74%) patients underwent adjuvant therapy: radiation ther-
apy in 29%, chemotherapy in 26%, and both in 18%.
Mean follow-up was 32.5 months. Ninety-nine patients
(54%) died, 21 of causes other than the tumor; 65 (37%)
patients are alive and free of disease, and 11 are alive with
recurrence. Recurrence occurred in 89 (51%) patients; the
site of the first recurrence was distant in 49 (55%) patients,
locoregional in 21 (24%), and both in 19 (21%). Brain was
the most common site of metastasis (33 cases; 37%). Distant
metastases (with or without locoregional involvement) were
present in 36 (84%) of 43 nonresponders and in 32 (70%) of
46 responders (P ¼ .116). Patients with persistent N2 dis-
ease had a distant metastases rate higher than that of patients
whose disease was downstaged (n ¼ 53/64, 83%, versus
n ¼ 15/25, 60%; P ¼ .023).
Overall 5-year survival was 30%, with a median survival
time (MST) of 34.7 months. Median time to recurrence was
13.7 months (range 2.9–64.8 months). Five-year PFS was
29%, and median PFS time was 22.9 months.ery c August 2010
TABLE 3. Univariate analysis of overall survival
Variable
Five-year
survival (%) MST (mo) P value
Predicted postoperative FEV1 (%)
<40 8% 16.4 .015
40 29% 34.7
Clinical N2 levels
Single 34% 39.2 .067
Multiple 22% 25.9
No. of CT cycles
<3 17% 21.1 .0001
3 38% 47.6
CT response
Objective response 42% 50.8 .0001
Stable disease 10% 19.0
Type of resection
Pneumonectomy 23% 25.9 .054
(Bi)lobectomy 33% 39.2
Pathologic T
T0þT1 49% 47.6 .001
T2 34% 29.8
T3þT4 17% 24.9
Pathologic N
N0 44% 57.6 .003
N1 42% 44.0
N2 22% 24.9
Pathologic stage
0þ Iþ II 44% 57.6 .0008
IIIA 27% 27.9
IIIBþ IV 0% 21.4
Radicality
Yes 32% 35.8 .002
No 0% 20.3
N downstaging
Yes 45% 50.9 .0008
No 22% 24.9
Histopathologic response
>90% 47% 47.6 .038
90% 27% 27.6
Significant or nearly significant associations are reported. MST, Median survival time;
FEV1, forced expiratory volume in 1 second; CT, chemotherapy.
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(Table 3). Clinical stage, method of staging, and administra-
tion of adjuvant therapy did not affect survival. Patients
whose disease was staged by surgery had an MST of 34.3
months versus 34.7 for those staged by imaging
(P ¼ .862). Survival curves according to clinical response
to chemotherapy and nodal downstaging are shown in
Figure 1, a and b. Responders with persistent N2 disease
(n ¼ 53) showed a 5-year survival and an MST of 30%
and 29.8 months, whereas responders with mediastinal
downstaging (n ¼ 56) showed 53% and 60.5 months, re-
spectively. Nonresponders with persistent N2 (n ¼ 54) had
a 5-year survival of 12% and an MST of 19 months, whereas
nonresponders with downstaging (12 patients only) had anThe Journal of Thoracic and CaMST of 33.4 months. Responders undergoing pneumonec-
tomy showed a 5-year survival of 34% and an MST of
35.2 months versus 6% and 15.4 months for nonresponders
(P ¼ .001); responders undergoing (bi)lobectomy had
a 5-year survival of 44% and an MST of 52.2 months versus
13% and 19.9 months for nonresponders (P ¼ .0004).
PFS was significantly affected with the same variables as
overall survival: median PFS time was 32.7 and 15.3 months
for responders and nonresponders, respectively, and 47.3
and 17.3 months for downstaged and nondownstaged
patients.
For 10 patients having complete pathologic remission,
MST was 45.7 months. Three died, 2 with disease relapse
at 36 and 39 months; 2 were alive with recurrence at 29
and 32 months; 5 were alive without recurrence.
The independent effect on survival of significant variables
was analyzed using the Cox regression model. Because re-
sponse to chemotherapy, nodal downstaging, and histopath-
ologic response were highly correlated, 3 separate models
were created (Table 4). The 3 variables remained significant
predictors of survival.
We matched response to chemotherapy, nodal downstag-
ing, and histopathologic response to all the other variables.
Histology was correlated to response to chemotherapy and
histopathologic response: adenocarcinomas showed a lower
rate of clinical response than did other histologic types (52%
vs 71%; P¼ .012) and a lower rate of major histopathologic
response (13% vs 26%; P ¼ .041). Patients having 3 or
more cycles of chemotherapy had a higher rate of clinical re-
sponse, downstaging, and major histopathologic response
than those having fewer than 3 cycles (73% vs 46% for clin-
ical response, P ¼ .0001; 47% vs 26% for downstaging,
P ¼ .004; 27% vs 10% for histopathologic response), but
in many patients chemotherapy was stopped after 2 cycles
if no response was observed. No association was found
when comparing type of chemotherapy regimen and number
of cycles of chemotherapy, clinical response, or downstag-
ing. Patients whose disease was downstaged required a pneu-
monectomy less frequently than patients with persistent N2
disease (34% vs 51%, respectively; P ¼ .028) and they
required more frequently a sleeve resection. No difference
was found in clinical response or downstaging with respect
to the method of staging: objective response rate was 58% in
surgically staged patients versus 65% in patients staged by
imaging (P ¼ .111); N downstaging rate was respectively
40% versus 38% (P ¼ .829).
Clinical response and mediastinal downstaging were
highly related: 51% of responders were also downstaged
versus only 18% of nonresponders (P ¼ .0001). Sensitivity
and specificity of restaging CT scan to predict mediastinal
downstaging were 82.3% and 50.4%, respectively; nega-
tive and positive predictive values were 81.8% and
51.3%; accuracy was 62.8%. Clinical response was also
highly related to histopathologic response: 30% of clinicalrdiovascular Surgery c Volume 140, Number 2 359
FIGURE 1. A, Survival by clinical response to chemotherapy. SD, Stable disease; OR, objective response. Five-year survival was 42% and 10% for re-
sponders and nonresponders, respectively. Median survival time was 50.8 and 19.0 months (P< .01). B, Survival by pathologic mediastinal downstaging.
Five-year survival was 45% and 22% for patients with downstaged and persistent N2 disease, respectively. Median survival time was 50.9 and 24.9 months
(P< .01).
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nonresponders.
DISCUSSION
The optimal treatment for N2 NSCLC remains controver-
sial. In the 1990s, 3 randomized trials reported an improved360 The Journal of Thoracic and Cardiovascular Surgsurvival for patients treated with induction chemotherapy
followed by surgery compared with surgery alone.6-8
These results were not confirmed by some subsequent
randomized studies, such as the large trial of Depierre and
associates17 and the trial of the Japan Clinical Oncology
Group.18 Furthermore, more recently, the potential role ofery c August 2010
TABLE 4. Multivariate analysis of survival
Model 1 Model 2 Model 3
Variable HR P value HR P value HR P value
Age, y (70 vs<70) 1.80 .064 1.81 .059 1.89 .053
Sex (M vs F) 1.63 .134 1.43 .209 1.61 .097
Predicted postoperative FEV1,% (<40 vs 40) 2.34 .012 2.31 .014 1.90 .063
cN2 levels (single vs multiple) 0.71 .146 0.79 .306 0.70 .125
Method of staging (imaging vs surgery) 0.78 .287 0.91 .671 0.86 .493
No. of CT cycles (<3 vs 3) 2.08 .001 2.45 .001 2.54 .001
Type of resection (lobectomy vs pneumonectomy) 0.91 .676 0.82 .393 0.79 .282
pStage (0, I, II vs III, IV) 0.55 .029 — — — —
Radicality (R0 vs R1, R2) 0.59 .173 0.54 .103 0.59 .171
Response to CT (OR vs SD) 0.47 .002 — — — —
N downstaging (yes vs no) — — 0.51 .007 — —
Histopathologic response (>90% vs 90%) — — — — 0.35 .005
HR, Hazard ratio; CT, chemotherapy; OR, objective response; SD, stable disease. Model 1 contains clinical response as a predictor variable, model 2 contains N downstaging, and
model 3 histopathologic response. Pathologic stage was not entered in models 2 and 3 because of high correlation with nodal downstaging and histopathologic response.
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ered. The EORTC trial13 did not find difference in survival
between surgery and radiation therapy after chemotherapy,
but only patients with unresectable disease were enrolled,
for which the role of surgery is doubtful. By contrast, the
North American Intergroup 0139 trial12 compared definitive
chemoradiation versus chemoradiation followed by surgery
in patients with potentially resectable N2 disease: an im-
provement in PFS was found in the surgical arm but there
was no difference in overall survival. This lack of difference
was attributed to high mortality after pneumonectomy
(26%), and the authors concluded that a trimodality ap-
proach is likely better if lobectomy can be done. However,
the great heterogeneity of N2 patients and different selection
criteria for multimodality treatment make results from the
literature difficult to evaluate.
It is nowadays widely accepted that induction chemother-
apy is safe and feasible and may increase resectability rate
and that complete surgical resection is essential to achieve
satisfactory survival.1,4,5,10,13,19,20 Therefore, we focused
only on patients with potentially resectable disease before
chemotherapy and who underwent surgery with a curative
intent to identify those who may definitely benefit from
surgical resection.
In our series we found an overall 5-year survival of 30%
and an MST of 34.7 months, with an improved outcome for
clinical responders and downstaged patients. These results
are comparable with those reported by other authors1,4,20,21
and seem better than survivals observed in the EORTC and
Intergroup trials,12,13 as in other nonrandomized studies.5,22
In our experience, mediastinoscopy was not routinely per-
formed and PET scan has been widely used only since 2004;
thus, there are patients whose disease was staged by CT scan
only. This could lead to clinical overstaging owing to false
positive results at CT. However, this subgroup represents
a minority of patients (32%) and 61% of them were defi-
nitely N2, with lymph node involvement proved postopera-The Journal of Thoracic and Catively; the remaining (n¼ 22) were specially selected only in
case of bulky N2 disease and/or multiple station involve-
ment, where CT scan specificity is higher. Moreover, no dif-
ference was found in clinical response, nodal downstaging,
and survival (at univariate and multivariate analysis) with re-
spect to the method of staging; this demonstrates that the
false positive N2 inclusions are rare.
The rate of clinical response to chemotherapy was high
(62%) and reflects data presented in the literature, where ob-
jective responses were observed in more than 50% of
cases.1,3-5,7,10,13,17,20 Some investigators have reported that
response to chemotherapy is a strong prognostic
factor.1,5,10 Accordingly, in our analysis clinical response
appeared to be the most important predictor of survival.
In agreement with many authors, we found that mediasti-
nal nodal downstaging on the resected specimen is a power-
ful and independent prognostic factor.3,5,10,13,19,20,22 This
suggests that the clearance of mediastinal disease may be
a marker for low risk of systemic disease and effectiveness
of chemotherapy. Our finding that distant metastases were
less frequent in downstaged patients confirms that
hypothesis. Unfortunately, this factor is based on
a posthoc analysis and it is useless to select patients for
surgery, unless a reliable restaging is available.
However, to date, there are insufficient data to exclude pa-
tients with resectable, persistent N2 disease from surgery,
because some of them can be cured. In our series this sub-
group did not show disappointing survivals, especially in
case of previous response to chemotherapy (MST of 29.8
months and 5-year survival of 30% in responders with per-
sistent N2). The presence of limited disease in mediastinal
nodes of many responders (nodal micrometastases in 62%
of 53 false positives on CT scan) and the fact that clinical re-
sponse takes into account also tumor regression, not only no-
des, may partly explain why this subgroup of patients with
N2 disease achieved a better prognosis. The same results
were reported by other authors.21 These findings suggestrdiovascular Surgery c Volume 140, Number 2 361
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tive of the residual mediastinal nodal status. Conversely, sur-
vival for nonresponders was poor, even if complete resection
was performed, as reported also by others.1,5,19
In agreement with other reports, in our study the degree of
clinical response was not a perfect predictor of pathologic
response.1,10,19,21 Therefore, some authors advocated the
importance of invasive restaging.4,21,23 In our series,
survival for responders with persistent N2 disease was
satisfactory and this may suggest no need for invasive
restaging in these patients, also accounting for relatively
high morbidity and low sensitivity of re-mediastinoscopy.
For nonresponders, survival was somewhat acceptable
only if nodal downstaging was achieved; nevertheless, this
event was quite uncommon (only 12 patients in our series),
inasmuch as sensitivity of CT scan in restaging was much
higher than specificity. Survival for nonresponders with per-
sistent N2 disease was very disappointing. Nevertheless, if
we choose to contraindicate surgery for all nonresponding
patients, we may lose a therapeutic option for the small group
of responders with downstaging. Thus, an invasive restaging
should be advisable in case of absence of clinical response.
Some authors have recently reported their experience using
endobronchial ultrasonography for lung cancer staging,
and results were satisfying and comparable with mediastino-
scopy.24,25 Given that mediastinoscopy after endobronchial
ultrasonography is easier, safer, and more sensitive than re-
mediastinoscopy, if a reliable staging can be done by endo-
bronchial ultrasonography, then mediastinoscopy could be
proposed for restaging in selected patients.
In patients with persistent N2 tumor, other N-related vari-
ables may have a role, such as bulky N2, the level of involve-
ment, or the number of involved levels.2,5,12 In our series,
only bulky N2 was a negative predictor of survival in case
of persistent nodal disease at operation; no clinical
variables related to N2 were found to be associated with
survival, except the number of involved levels, nearly
significant at univariate analysis.
The large number of pneumonectomies in this series is
common for advanced NSCLC. The mortality rate for pneu-
monectomy, significantly lower compared with data from
the Intergoup 0139 trial,12 was acceptable and, according
to other authors, did not negatively affect the outcome of
these patients.5,13,17,18,21,22 This lower mortality for
pneumonectomy and a population with likely less extensive
N2 disease may partly explain the better survival of our
series compared with the Intergroup trial. In a previous
study, we11 found a 6%mortality rate for pneumonectomy af-
ter induction chemotherapy. The lower survival for patients
requiring pneumonectomy is related to their higher pathologic
stage; type of resection did not result as an independent predic-
tor of survival. Interestingly, we observed that survival was
very low in 31 nonresponder patients requiring a pneumonec-
tomy, with 5-year survival of 6% and MST and median PFS362 The Journal of Thoracic and Cardiovascular Surgtime of 15.4 and 12.6 months, respectively. In case of lobec-
tomy, survival was better but remained rather disappointing.
The number of cycles of chemotherapy had a strong im-
pact on survival, and this further proves the effectiveness
of chemotherapy in responders; the variable is however
highly related with clinical response and downstaging. It is
a common policy, among our referring physicians, to stop
chemotherapy if no response is detected at an interim restag-
ing after 2 cycles of chemotherapy.
Most patients in our selection underwent adjuvant
therapy, and the variability of protocols and regimens could
represent a confounding factor. However, no difference in
adjuvant therapy was found with respect to clinical response
or pathologic nodal status; moreover, no association be-
tween adjuvant treatment and survival was observed.
Inasmuch as death often followed recurrence within
a short interval, the Kaplan–Meier curves for overall sur-
vival and PFS were quite similar, whereas MST was obvi-
ously reduced. The analysis of PFS did not really differ
from overall survival.
Although the rate of distant metastases was reduced in
downstaged patients and despite the large use of postoperative
chemotherapy, distant recurrence remained the main cause of
death in our series, as well as in many other reports,1,3,5,13,23
also for patients with nodal disease clearance. This shows
that further improvement of chemotherapy protocols is
needed. Furthermore, the frequency of brain metastases
raises the question whether prophylactic cranial irradiation
should be added to therapeutic protocols.5,19
In conclusion, in selected patients radical surgery after
chemotherapy provides favorable long-term survivals, with
low postoperative mortality, even in case of pneumonec-
tomy. Clinical response and nodal downstaging are the
best predictors of survival. For responders, survival remains
satisfying even in case of persistent N2 disease. For nonre-
sponders, surgery appears to be contraindicated when
a pneumonectomy is required.References
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